Bellerophon Therapeutics, Inc.
BLPH
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 5.64M | 5.64M | 5.64M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.64M | 5.64M | 5.64M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5.64M | 5.64M | 5.64M | -- | -- |
| SG&A Expenses | 6.97M | 6.71M | 6.40M | 6.02M | 5.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.68M | 19.62M | 20.90M | 22.38M | 21.57M |
| Operating Income | -11.04M | -13.98M | -15.26M | -22.38M | -21.57M |
| Income Before Tax | -10.53M | -13.68M | -15.06M | -22.25M | -21.50M |
| Income Tax Expenses | -1.28M | -1.28M | -3.69M | -2.42M | -2.42M |
| Earnings from Continuing Operations | -9.25 | -12.40 | -11.37 | -19.83 | -19.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.25M | -12.40M | -11.37M | -19.83M | -19.09M |
| EBIT | -11.04M | -13.98M | -15.26M | -22.38M | -21.57M |
| EBITDA | -11.03M | -13.95M | -15.22M | -22.32M | -21.49M |
| EPS Basic | -0.83 | -1.20 | -1.21 | -2.08 | -2.00 |
| Normalized Basic EPS | -0.60 | -0.83 | -0.99 | -1.46 | -1.41 |
| EPS Diluted | -0.84 | -1.21 | -1.22 | -2.08 | -2.00 |
| Normalized Diluted EPS | -0.60 | -0.83 | -1.00 | -1.46 | -1.41 |
| Average Basic Shares Outstanding | 44.39M | 41.70M | 39.02M | 38.20M | 38.14M |
| Average Diluted Shares Outstanding | 44.64M | 41.95M | 39.26M | 38.20M | 38.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
